|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
9
|
|
pubmed:dateCreated |
2008-8-7
|
|
pubmed:abstractText |
Patients with low-risk neutropenic fever as defined by the Multinational Association of Supportive Care in Cancer (MASCC) score might benefit from ambulatory treatment. Optimal management remains to be clearly defined, and new oral antibiotics need to be evaluated in this setting.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
0941-4355
|
|
pubmed:author |
pubmed-author:BachelotThomasT,
pubmed-author:BironPierreP,
pubmed-author:ChelghoumMariaM,
pubmed-author:ChvetzoffGiselleG,
pubmed-author:DevauxYvesY,
pubmed-author:DussartSophieS,
pubmed-author:FuhrmannChristineC,
pubmed-author:GeoffroisLionelL,
pubmed-author:GhesquieresHervéH,
pubmed-author:LancryLaurenceL,
pubmed-author:RodriguesIsabelleI,
pubmed-author:SebbanCatherineC
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
16
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1017-23
|
|
pubmed:meshHeading |
pubmed-meshheading:18197434-Administration, Oral,
pubmed-meshheading:18197434-Adult,
pubmed-meshheading:18197434-Aged,
pubmed-meshheading:18197434-Aged, 80 and over,
pubmed-meshheading:18197434-Anti-Bacterial Agents,
pubmed-meshheading:18197434-Anti-Infective Agents,
pubmed-meshheading:18197434-Antineoplastic Agents,
pubmed-meshheading:18197434-Aza Compounds,
pubmed-meshheading:18197434-Ceftriaxone,
pubmed-meshheading:18197434-Female,
pubmed-meshheading:18197434-Fever,
pubmed-meshheading:18197434-Humans,
pubmed-meshheading:18197434-Infusions, Intravenous,
pubmed-meshheading:18197434-Male,
pubmed-meshheading:18197434-Middle Aged,
pubmed-meshheading:18197434-Neoplasms,
pubmed-meshheading:18197434-Neutropenia,
pubmed-meshheading:18197434-Patient Discharge,
pubmed-meshheading:18197434-Quinolines,
pubmed-meshheading:18197434-Risk Factors,
pubmed-meshheading:18197434-Time Factors
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Oral moxifloxacin or intravenous ceftriaxone for the treatment of low-risk neutropenic fever in cancer patients suitable for early hospital discharge.
|
|
pubmed:affiliation |
Centre Léon Bérard, 28 rue Laennec, Lyon, France. sebban@lyon.fnclcc.fr
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, Non-P.H.S.,
Randomized Controlled Trial
|
